Top Health Tech Companies in Atlanta, GA (224)

Strong Revenue Growth: Reported revenue has been rising at a double‑digit pace across fiscal 2025 and the first half of 2026, with both Q1 and Q2 showing solid year‑over‑year increases. Management also raised full‑year 2026 revenue guidance, indicating confidence in continued expansion.

Profitability: Profitability is strong, with adjusted EBITDA growing year over year and margins holding in the low‑40s through fiscal 2025 and recent quarters. The company also reported positive net income and healthy cash generation.

Customer Loyalty & Retention: Net revenue retention remained expansionary and the number of larger clients increased year over year. Subscription revenue grew faster than total revenue in recent periods, suggesting deeper adoption within the existing base.

Market Expansion: Operations have expanded from 3 to 14 and then 20+ states, with 8,800+ patients served and 17,700+ completed service requests by April 2025. Ongoing recruitment of transportation partners across Georgia and South Carolina underscores continued footprint growth.

Product Line Growth: Offerings now span transportation, interpretation, prescription delivery, post-procedure care, home health, and telemedicine within an integrated coordination platform. This broadened scope indicates expansion beyond a pure NEMT broker into a wider patient-access solution.

Investor Backing & Capital Strength: External sources cite roughly mid–single-digit millions raised across multiple seed rounds, including an oversubscribed Seed-3 in early 2023. Participation in programs with institutions such as Morgan Stanley and Mastercard Start Path signals ongoing investor support.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list and an Inc. profile noting 27% three-year growth for 2026 indicate sustained top-line expansion.

Market Expansion: Acquisitions in 2023 (ABA Therapy Billing & Insurance Services) and 2025 (Joshin), plus the addition of a Chief Revenue Officer and an SVP of Enterprise Sales, point to expansion across providers, disability support, and enterprise channels.

Innovation-Driven Growth: New AI-enabled capabilities for behavioral-health workflows and analytics recognition suggest product momentum that supports continued scaling.

Strong Market Position & Advantage: Evidence suggests MEDITECH holds a top-three position in U.S. inpatient EHRs, with recognized leadership in community/small hospitals and in Canada. Industry accolades like repeated Best in KLAS for Expanse in small-acute segments reinforce standing in its core markets.

Market Expansion: Recent enterprise deployments (such as HCA go-live waves), continuing community/rural wins via MaaS, and new international go-lives point to selective expansion. Coverage notes active participation in global contracting cycles and growing cloud-delivered implementations.

Customer Loyalty & Retention: Independent tracking indicates many legacy customers are migrating to Expanse rather than switching vendors. Continued segment recognition aligns with durable satisfaction in core community tiers.

Strong Revenue Growth: Consistent disclosures describe revenue scaling from earlier sub‑billion levels to a multi‑billion business, with segment updates indicating continued expansion. Parent commentary cites rising sales and operating income supported by new launches and portfolio additions.

Innovation-Driven Growth: A steady cadence of FDA approvals and U.S. launches (e.g., next‑generation LifeVest and Zenix) alongside acquisitions such as select Vyaire ventilator lines signals a pipeline that supports growth. Feedback suggests refreshed offerings in core categories are intended to drive adoption across EMS, hospital, and outpatient settings.

Strong Market Position & Advantage: ZOLL is portrayed as the clear leader in wearable defibrillators and a top‑tier competitor in external defibrillation, operating globally with strong backing from its parent. Evidence of federal procurement wins and an expanded installed base through acquisitions indicates durable competitive standing.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.

Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.

Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.

Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.

Strong Revenue Growth: Revenue is rising with multiple quarters of year-over-year increases, a higher 2025 premium and service revenue outlook, and record trailing-twelve-month totals.

Strong Market Position & Advantage: The company is the largest Medicaid managed care organization and the leading ACA Marketplace carrier, with nationwide operations and sustained industry recognition.

Market Expansion: Membership is growing in the ACA Marketplace and Medicare prescription drug plans, alongside ongoing footprint expansion and key state Medicaid contract wins.

Strong Market Position & Advantage: Industry analyses frequently describe external‑beam radiotherapy as a Varian–Elekta near‑duopoly, with Varian often cited at or near the top. Feedback suggests a large installed base, leading software stack, and a broad global service footprint reinforce this position.

Strong Revenue Growth: Company and trade updates state the Varian segment has posted year‑over‑year revenue growth across multiple recent periods within Siemens Healthineers, alongside positive order momentum and a growing backlog. Feedback suggests recent quarterly trends point to continued demand for systems, software, and services.

Strategic Partnerships: Integration with Siemens Healthineers provides access to imaging, diagnostics, and digital platforms, enabling end‑to‑end oncology workflows and cross‑selling advantages. Feedback suggests this parent‑level backing strengthens global reach and execution in tenders.